Chromophobe Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma, Kidney Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma
Conditions
Brief summary
This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.
Interventions
OTHERProteomic profiling of urinary EVs
EV isolation and mass spectrometry.
PROCEDUREBlood sample collection
Blood samples collected pre- and post-nephrectomy
Sponsors
Mayo Clinic
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Urine sample in existing biorepository * High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines * Scheduled to undergo nephrectomy
Exclusion criteria
* Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Differentiate tumor-derived extracellular vesicle (tdEV) surface proteins expressed in benign vs malignant renal tumors | Baseline | Differential protein expression analysis will be performed on stored urine samples from a biorepository to identify tdEV proteins in each renal cell carcinoma (RCC) subtype (clear-cell, papillary, and chromophobe) versus benign. |
| Prediction of metastasis after surgery | Perioperative (pre- and post-nephrectomy), | Blood samples will be collected pre-and post-nephrectomy to asses for tdEV levels which will be correlated with clinicopathological features to test whether tdEV levels can be used to better predict likelihood of metastasis in patients undergoing curative-intent radical nephrectomy. |
Countries
United States
Contacts
CONTACTClinical Trials Referral Office
PRINCIPAL_INVESTIGATORFabrice Lucien-Matteoni, MD
Mayo Clinic
Outcome results
None listed